Essentially agree, plytle. I hope they can enroll the final patients this quarter (a quarter behind schedule, far from the end of the world, but who knows what future issues with enrollment will emerge), and complete the trial by end of Q1 of 2013, and get it into the hands of the FDA within a few months thereafter. The main issue with delay is expense, and the more expense the more ultimate dilution is likely.

Question on the type 2 with the placebo: how does that trial work? You tell the patient to check his/her blood a certain amount of time after the inhalation (not knowing whether its insulin laden or not), and if the reading is not right, you then take an injection of the real stuff?

I guess no danger in overdosing on insulin if the inhaler was insulin-laden and the patient went ahead and injected some insulin? At best, sounds like a pain for the participant who gets the placebo. And how long must that go on before he says that he either has the placebo or Afrezza ain't working for him? Seems like the placebo group should be "outed" pretty quickly.

Perhaps I have the above all wrong, can someone explain?